IPSEN – Buy-back programme – Art 5 of MAR – Week 22 – 2023

Back

IPSEN – Buy-back programme – Art 5 of MAR – Week 22 – 2023

- 06 June 2023 - 1 mins read

Aggregated presentation by day and by market

Name of issuer

Identification code of issuer (Legal Entity Identifier)

Day of transaction

Identification code of financial instrument

Aggregated daily volume (in number of shares)

Daily weighted average price of the purchased shares *

Market (MIC Code)

IPSEN549300M6SGDPB4Z94P1101/06/2023FR0010259150284111,21AQEU
IPSEN549300M6SGDPB4Z94P1101/06/2023FR0010259150690111,19CEUX
IPSEN549300M6SGDPB4Z94P1101/06/2023FR001025915024111,26TQEX
IPSEN549300M6SGDPB4Z94P1101/06/2023FR00102591502 979110,74XPAR
IPSEN549300M6SGDPB4Z94P1102/06/2023FR0010259150712110,99AQEU
IPSEN549300M6SGDPB4Z94P1102/06/2023FR0010259150549110,94CEUX
IPSEN549300M6SGDPB4Z94P1102/06/2023FR0010259150458111,01TQEX
IPSEN549300M6SGDPB4Z94P1102/06/2023FR00102591503 681110,81XPAR
* Two-digit rounding after the decimal TOTAL9 377110,86 

Attachment

Related Press Releases

Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
24 April 2024 7 mins read

Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
22 April 2024 5 mins read

Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
Ipsen publishes its 2023 Universal Registration Document
17 April 2024 4 mins read

Ipsen publishes its 2023 Universal Registration Document
Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital
08 April 2024 1 mins read

Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
02 April 2024 7 mins read

Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital
07 March 2024 1 mins read

Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital
Ipsen S.A. publishes its 2023 Consolidated Financial Statements
15 February 2024 1 mins read

Ipsen S.A. publishes its 2023 Consolidated Financial Statements
Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA  
13 February 2024 14 mins read

Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA  
Building on solid FY 2023 results, Ipsen anticipates four launches in 2024
08 February 2024 8 mins read

Building on solid FY 2023 results, Ipsen anticipates four launches in 2024
Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital
06 February 2024 1 mins read

Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital